Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Research

Phase 3 Trials Patient Outcomes Fast Track Designation by FDA Patient Care Eli Lilly

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

The results pave the way for a regulatory submission this year targeting a 2026 cardiovascular label expansion.

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion